Want to see MNPR full AI Analyst Report?
Top Page
Monopar Therapeutics Inc
(NASDAQ:MNPR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$104.00
▲(84.99% Upside)
Action:Reiterated
Date:06/30/26
The score is primarily constrained by weak financial performance (pre-revenue, escalating losses and cash burn), with limited technical/valuation support due to missing indicators and non-meaningful P/E. Offsetting this, recent corporate events are meaningfully positive, including FDA designation and additional Phase 2/3 data updates that strengthen the late-stage asset narrative.
Positive Factors
Phase 3 Efficacy
Robust, durable Phase 3 neurologic benefit and multi-year follow-up across pooled studies materially de-risks the lead program. Sustained efficacy and favorable safety across 266 patients and 645 patient-years support a credible regulatory filing path and long-term clinical value.
Negative Factors
Pre-revenue Operations
As a development-stage biotech with no commercial revenue, Monopar has limited internal ability to fund operations. Worsening net losses increase reliance on external financing or partnerships, making long-term viability contingent on clinical/regulatory success and capital access.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 Efficacy
Robust, durable Phase 3 neurologic benefit and multi-year follow-up across pooled studies materially de-risks the lead program. Sustained efficacy and favorable safety across 266 patients and 645 patient-years support a credible regulatory filing path and long-term clinical value.
Read all positive factors
Monopar Therapeutics Inc (MNPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$700.05M
Dividend YieldN/A
Average Volume (3M)149.81K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue GrowthN/A
EPS Growth40.38%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.07
Shares Outstanding6,699,062
10 Day Avg. Volume167,624
30 Day Avg. Volume149,806
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-24.23
Forecast
1Y Price Target
$113.33Price Target Upside101.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.77
Revenue Forecast (FY)N/A
Monopar Therapeutics Inc Business Overview & Revenue Model
Company Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; ...
How the Company Makes Money
null...
Monopar Therapeutics Inc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.64M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net Income | -14.98M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
Balance Sheet | ||||||
| Total Assets | 137.98M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Cash, Cash Equivalents and Short-Term Investments | 137.49M | 140.40M | 60.21M | 7.27M | 13.12M | 20.30M |
| Total Debt | 131.56K | 154.92K | 0.00 | 0.00 | 8.41K | 0.00 |
| Total Liabilities | 2.59M | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M |
| Stockholders Equity | 135.39M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
Cash Flow | ||||||
| Free Cash Flow | -10.01M | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Operating Cash Flow | -10.01M | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Investing Cash Flow | -68.71M | -63.45M | -14.34M | 4.93M | -4.92M | 0.00 |
| Financing Cash Flow | 91.49M | 91.57M | 59.29M | 2.03M | 32.87K | 10.88M |
Monopar Therapeutics Inc Technical Analysis
Positive
56.22
Price Trends
69.64
Positive
62.77
Positive
69.50
Positive
Market Momentum
10.60
Negative
83.39
Negative
78.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Positive. The current price of 56.22 is below the 20-day moving average (MA) of 83.60, below the 50-day MA of 69.64, and below the 200-day MA of 69.50, indicating a bullish trend. The MACD of 10.60 indicates Negative momentum. The RSI at 83.39 is Negative, neither overbought nor oversold. The STOCH value of 78.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MNPR.
Monopar Therapeutics Inc Risk Analysis
Monopar Therapeutics Inc disclosed 77 risk factors in its most recent earnings report. Monopar Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monopar Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $465.73M | -2.14 | -121.71% | ― | ― | ― | |
56 Neutral | $474.52M | -2.21 | -486.41% | ― | 395.85% | 21.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $700.05M | -51.30 | -12.84% | ― | ― | 40.38% | |
47 Neutral | $383.66M | -1.54 | -61.41% | ― | 8.16% | -434.76% | |
46 Neutral | $90.25M | -1.96 | -95.50% | ― | -10.71% | 28.59% | |
46 Neutral | $51.75M | -1.51 | -81.25% | ― | ― | 28.17% |
* Healthcare Sector Average
MNPR
Monopar Therapeutics Inc
106.60
69.73
189.12%
CRDF
Cardiff Oncology
1.33
-2.74
-67.32%
VNDA
Vanda
6.24
1.50
31.65%
VSTM
Verastem
5.53
0.85
18.04%
MREO
Mereo Biopharma Group Plc
0.34
-1.28
-79.19%
SLN
Silence Therapeutics
9.09
2.65
41.15%
Monopar Therapeutics Inc Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Monopar Wins FDA Rare Pediatric Disease Designation
Positive
Jun 30, 2026
On June 30, 2026, Monopar Therapeutics announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to its late-stage Wilson disease candidate ALXN1840 (tiomolibdate choline). The designation, aimed at serious co...
Business Operations and StrategyProduct-Related Announcements
Monopar Highlights Positive Phase 3 Wilson Disease Data
Positive
Jun 26, 2026
On June 26, 2026, Monopar Therapeutics announced new analyses from its Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) in Wilson disease, to be presented at the European Academy of Neurology Congress in Geneva from June 27–30, 2026. T...
Executive/Board ChangesShareholder Meetings
Monopar Shareholders Approve Directors, Pay and Incentive Plan
Positive
Jun 23, 2026
At its June 22, 2026 annual meeting, Monopar Therapeutics Inc. reported that shareholders representing a majority of the 6.7 million eligible common shares were present in person or by proxy, ensuring quorum and full voting power on governance mat...
Business Operations and StrategyProduct-Related Announcements
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
Positive
May 29, 2026
On May 29, 2026, Monopar Therapeutics presented results from a Phase 2 study of ALXN1840 (tiomolibdate choline) in patients with Wilson disease at the European Association for the Study of the Liver International Liver Congress 2026. The trial eva...
Business Operations and StrategyProduct-Related Announcements
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
Positive
May 19, 2026
On May 19, 2026, Monopar Therapeutics reported that Hepatology Communications published Phase 2 data showing its investigational drug ALXN1840 (tiomolibdate choline) significantly improved copper balance in nine patients with Wilson disease. The o...
Business Operations and StrategyProduct-Related Announcements
Monopar Highlights Strong Phase 3 Data for ALXN1840
Positive
Apr 20, 2026
On April 19, 2026, Monopar Therapeutics reported new analyses from the randomized Phase 3 FoCus trial showing that ALXN1840 (tiomolibdate choline) delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.